<i id='3075677491'><strike id='3075677491'><tt id='3075677491'><pre id='3075677491'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We
read more
ARIANADREHSLER/AFPviaGettyImagesWASHINGTON—TheCentersforDiseaseControlandPreventionrecommendedthiswe
read more
ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022
read moreFREDERICJ.BROWN/AFPviaGettyImagesThenumberofchildrenwhoreceivedtheirroutinevaccinationsdeclineddurin
